SUNG, YOUNG CHUL,成永喆,YANG, SEHWAN,梁世涣,BYUN, MI SUN,卞美仙,YANG, SANG IN,杨尙仁,楊尙仁,SHIN, EUN JU,辛恩朱
申请号：
TW104144638
公开号：
TW201636375A
申请日:
2015.12.31
申请国别(地区):
TW
年份:
2016
代理人:
摘要：
The present invention relates to a fusion polypeptide containing a glucagon-like peptide (GLP) and an immunoglobulin hybrid Fc, and more specifically, to a fusion polypeptide with an increased half-life and improved efficacy compared to the conventional fusion polypeptide based on the discovery of an immunoglobulin hybrid Fc suitable for GLP or analogs thereof, and a pharmaceutical composition for treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, containing the fusion polypeptide. The fusion polypeptide of the present invention has an increased half-life and improved resistance to DPP-4 enzyme compared to those of GLP-1 and GLP-2, and it thus has improved drug efficacy in treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, compared to those of the conventional drugs. Accordingly, the fusion polypeptide of the present invention can be effectively applied to pharmaceutical drugs.本發明係關於含有類升糖素肽(GLP)及免疫球蛋白Fc的融合多肽，且更具體地，係關於基於適合於GLP或其類似物的免疫球蛋白雜合Fc的發現，而相較於傳統融合多肽具有增加的半衰期及改良的效能的融合多肽，以及用於治療糖尿病、炎性腸疾病、抗癌化療引起的腸黏膜炎及下痢、或短腸症候群之含有該融合多肽的醫藥組成物。本發明之融合多肽，相較於GLP-1及GLP-2者，具有增加的半衰期及對DPP-4酵素的改良抗性，且因而相較於傳統藥物，其為於治療糖尿病、炎性腸疾病、抗癌化療引起的腸黏膜炎或下痢、或短腸症候群具有改良的藥物效能。因此，本發明之融合多肽可有效地應用於醫學藥物。
